March 8, 2022
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
March 8, 2022
Publication of Definitive Interim Result for Vifor Pharma Tender Offer: CSL Behring AG Declares Offer Successful
CSL Behring AG, a wholly-owned subsidiary of global biotechnology leader CSL Limited has announced the definitive notice of the Interim Result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.
March 8, 2022
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
Valneva SE has announced successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553.
March 7, 2022
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for Skin Cancer Drug
Evaxion Biotech has now finalized recruitment for Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma patients.
March 7, 2022
Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise
In this newly created role reporting to the CEO, Dr. Yver will be accountable for the company’s overall development strategy, including scientific, clinical and regulatory matters, and will continue to provide support to research and clinical development teams.
March 7, 2022
Pharmaceutical Companies to Support Ukrainian People
Some pharmaceutical companies are donating money to support people in Ukraine and are condemning the war and violence in Ukraine.…
March 7, 2022
Abbott to Donate $2M to Ukrainian People
Abbott stands with the international community condemning the war and the violence in Ukraine against its people, and calls for peace.
March 7, 2022
Ovoca Bio not Affected by Sanctions against Russia;
The Board of Ovoca Bio, an international biopharmaceutical company focusing on women’s health, has issued a statement in response to events in Ukraine and Russia.
March 7, 2022
Tollys and Gustave Roussy enter into new research agreement
Tollys has entered into a sponsored research agreement with Gustave Roussy.
March 6, 2022
Oncimmune Holdings in new commercial contract with 10 companies
Oncimmune Holdings has signed a commercial contract with a new top 10 global pharmaceutical company by revenue, initially focusing on the autoantibody profiling of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (“CIDP”).